Gilead Sciences Inc (XSGO:GILD)
$ 65.55 0 (0%) Market Cap: 84.47 Bil Enterprise Value: 104.94 Bil PE Ratio: 188.33 PB Ratio: 4.82 GF Score: 74/100

Gilead Sciences Inc Oncology Deep Dive Transcript

Apr 14, 2022 / 05:00PM GMT
Release Date Price: $65.55
Jacquie Ross
Gilead Sciences, Inc. - VP of IR

Good morning or good afternoon to you all, and thank you for joining us for our Gilead Oncology Deep Dive. We're looking forward to spending some time with you today discussing our oncology portfolio, focusing on our pipeline, which is addressing a broad range of solid tumors and heme malignant disease. Our presenters today are Daniel O'Day, Gilead's Chairman and Chief Executive Officer; Bill Grossman, our SVP and Head of our Oncology Therapeutic Area, Janet Dorling, our SVP of Global Commercial Product Strategy; See Phan, VP and Head of our Oncology Franchise for Breast; Bilal Piperdi, our VP of Oncology Clinical Development; Giri Ramsingh, Executive Director and Group Development Leader for Heme; Frank Neumann, our SVP and Global Head of Clinical Development for Kite; Bernard Fine, VP and Head of our Oncology Franchise, Early Development; and Jackson Egen, our VP of Research.

We have roughly 2 hours of prepared materials, after which we'll host an open Q&A session where you'll be able to ask a question live or submit a question through the Q

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot